775 — CK Life Sciences Intl (Holdings) Cashflow Statement
0.000.00%
Last trade - 00:00- HK$8.07bn
- HK$13.60bn
- HK$5.52bn
- 13
- 24
- 72
- 27
Annual cashflow statement for CK Life Sciences Intl (Holdings), fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 119 | 238 | 205 | 68.6 | -91.5 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 86.9 | 98.5 | 97.2 | 209 | 250 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 105 | -160 | -169 | 2.84 | -49.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 531 | 424 | 364 | 514 | 354 |
| Capital Expenditures | -380 | -217 | -217 | -292 | -199 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -77.5 | -40.6 | 195 | 224 | 103 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -457 | -258 | -22.1 | -68 | -96.6 |
| Financing Cash Flow Items | -134 | -98.1 | -163 | -321 | -335 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 169 | -220 | -515 | -478 | -342 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 262 | -68.2 | -199 | -27.6 | -110 |